WO2000033820A3 - Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen - Google Patents

Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen Download PDF

Info

Publication number
WO2000033820A3
WO2000033820A3 PCT/EP1999/009545 EP9909545W WO0033820A3 WO 2000033820 A3 WO2000033820 A3 WO 2000033820A3 EP 9909545 W EP9909545 W EP 9909545W WO 0033820 A3 WO0033820 A3 WO 0033820A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
cosmetic preparations
shell systems
core
nanoparticulate core
Prior art date
Application number
PCT/EP1999/009545
Other languages
English (en)
French (fr)
Other versions
WO2000033820A2 (de
Inventor
Robert Heger
Helmut Auweter
Joerg Breitenbach
Heribert Bohn
Original Assignee
Basf Ag
Robert Heger
Helmut Auweter
Joerg Breitenbach
Heribert Bohn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag, Robert Heger, Helmut Auweter, Joerg Breitenbach, Heribert Bohn filed Critical Basf Ag
Priority to US09/857,480 priority Critical patent/US7687071B1/en
Priority to JP2000586313A priority patent/JP2002531492A/ja
Priority to EP99963399A priority patent/EP1137404A2/de
Priority to CA002353809A priority patent/CA2353809A1/en
Publication of WO2000033820A2 publication Critical patent/WO2000033820A2/de
Publication of WO2000033820A3 publication Critical patent/WO2000033820A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nanopartikuläre Zubereitungen von pharmazeutischen und kosmetischen Wirkstoffen mit einer Kern-Schale Struktur, in denen der Wirkstoff im Kern röntgenamorph zusammen mit einer Polymermatrix vorliegt und die Schale aus einer stabilisierenden Hüllmatrix besteht.
PCT/EP1999/009545 1998-12-08 1999-12-07 Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen WO2000033820A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/857,480 US7687071B1 (en) 1998-12-08 1999-12-07 Nanoparticulate core shell systems and the use thereof in pharmaceutical and cosmetic preparation
JP2000586313A JP2002531492A (ja) 1998-12-08 1999-12-07 ナノ粒子状コア／シェル系、ならびに医薬品および化粧品におけるその使用
EP99963399A EP1137404A2 (de) 1998-12-08 1999-12-07 Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen
CA002353809A CA2353809A1 (en) 1998-12-08 1999-12-07 Nanoparticulate core-shell systems and use thereof in pharmaceutical and cosmetic preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856432A DE19856432A1 (de) 1998-12-08 1998-12-08 Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19856432.5 1998-12-08

Publications (2)

Publication Number Publication Date
WO2000033820A2 WO2000033820A2 (de) 2000-06-15
WO2000033820A3 true WO2000033820A3 (de) 2000-10-12

Family

ID=7890273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009545 WO2000033820A2 (de) 1998-12-08 1999-12-07 Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen

Country Status (7)

Country Link
US (1) US7687071B1 (de)
EP (1) EP1137404A2 (de)
JP (1) JP2002531492A (de)
CN (1) CN100346775C (de)
CA (1) CA2353809A1 (de)
DE (1) DE19856432A1 (de)
WO (1) WO2000033820A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
US6471951B1 (en) * 1999-04-30 2002-10-29 Color Access, Inc. Eyebrow pencil with agglomerated pigments
GB9911037D0 (en) * 1999-05-13 1999-07-14 Micap Limited Nicotine delivery service
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
AU2002364701B8 (en) * 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
DE10240956B4 (de) * 2002-09-05 2005-03-17 Christian-Albrechts-Universität Zu Kiel Heterogene Kern-Schale Mikrogele mit mehrstufigem Schaltverhalten
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10350528A1 (de) * 2003-10-29 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
DE10355400A1 (de) 2003-11-25 2005-07-07 Noack, Andreas, Dr. Multikomponenten Mineralstoffpräparate und Verfahren zur Herstellung von Multikomponenten-Mineralstoffpräparaten
EP1750669A1 (de) * 2004-05-04 2007-02-14 Boehringer Ingelheim International Gmbh Solide pharmazeutische form mit einem ltb4-antagonist
JP2008520735A (ja) * 2004-11-22 2008-06-19 ニュー‐ティーン カンパニー，インク． 局所用皮膚パッチ
US20110177306A1 (en) * 2004-12-17 2011-07-21 Mitsubishi Chemical Corporation Novel Core-Shell Structure
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
DE102005027333B4 (de) 2005-06-13 2017-04-13 Terra Nano Ltd. Nanoskalische Reaktivdesorption - ein Verfahren zur Herstellung kolloidalisierter Wirkstoff- oder Vitalstoffspezies, insbesondere entsprechender Wirkstoff- oder Vitalstoffkonzentraten sowie Vorrichtungen zur Durchführung derselben
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP2009513597A (ja) * 2005-10-27 2009-04-02 ビーエーエスエフ ソシエタス・ヨーロピア ナノ粒子活性成分製剤
CN101296616A (zh) * 2005-10-27 2008-10-29 巴斯夫欧洲公司 农业化学的纳米颗粒状活性成分配制剂
WO2007109244A2 (en) * 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
AU2007240986A1 (en) * 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
WO2008054508A2 (en) * 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
WO2008109483A1 (en) * 2007-03-02 2008-09-12 The Board Of Trustees Of The University Of Illinois Particulate drug delivery
WO2010005721A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
ES2776126T3 (es) 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
US8685538B2 (en) 2009-03-25 2014-04-01 Northeastern University Stable polyelectrolyte coated nanoparticles
CA2759807C (en) * 2009-04-23 2018-03-20 Sustained Nano Systems Llc Controlled release dispensing device
WO2011023446A1 (en) * 2009-08-31 2011-03-03 Technische Universität Graz Sensitive paints
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
JP5891175B2 (ja) 2009-12-11 2016-03-22 バインド セラピューティックス インコーポレイテッド 治療用粒子の凍結乾燥に対する安定製剤
EA201290497A1 (ru) * 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
WO2012140181A1 (de) 2011-04-15 2012-10-18 Basf Se Verfahren zur herstellung wässriger dispersionen aliphatischer polycarbonate
CN102406941B (zh) * 2011-07-29 2015-03-11 沈阳药科大学 含有改性明胶肽的纳米化难溶性活性组分及其制备方法
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
CN104812381B (zh) 2012-09-17 2018-01-26 辉瑞大药厂 用于制备治疗性纳米颗粒的方法
ES2873600T3 (es) * 2013-02-05 2021-11-03 1Globe Health Inst Llc Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos.
ME03435B (de) 2014-03-14 2020-01-20 Pfizer Therapeutische nanopartikel mit einem behandlungsmittel sowie verfahren zur herstellung und verwendung davon
JP6660372B2 (ja) 2014-08-07 2020-03-11 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 送達システム
CN105640819A (zh) * 2014-11-13 2016-06-08 广州十长生化妆品有限公司 一种具有嫩滑美白肌肤的去角质微球及其应用
CA3069155A1 (en) 2017-07-11 2019-01-17 Sustained Nano Systems Llc Radiation sterilization of hypercompressed polymer dosage forms
JP7493796B2 (ja) 2017-07-11 2024-06-03 サステインドナノシステムズエルエルシー 超圧縮医薬製剤
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
WO2019226571A1 (en) * 2018-05-19 2019-11-28 Gary Binyamin Foam formulations and delivery methods to the body
EP3804701A1 (de) * 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung einer pharmazeutischen formulierung mit kristallinen und amorphen anteilen eines wirkstoffes
WO2022174078A1 (en) * 2021-02-12 2022-08-18 Ephemeral Solutions, Inc. Particles containing coloring agents and methods of using the same
CN116459231B (zh) * 2023-05-23 2023-09-08 中国农业大学 一种温敏载药核壳纳米颗粒的制备及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275796A1 (de) * 1986-12-31 1988-07-27 Centre National De La Recherche Scientifique Herstellungsverfahren für kolloid-disperse Systeme aus einer Substanz in Form von Nanopartikeln
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO1995005164A1 (en) * 1993-08-12 1995-02-23 Kirsten Westesen Particles with modified physicochemical properties, their preparation and uses
WO1998014174A1 (en) * 1996-10-01 1998-04-09 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
NL194638C (nl) 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
DE3702029A1 (de) 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
DE3936053A1 (de) 1989-10-28 1991-05-02 Basf Ag Verfahren zur verbesserung der bioverfuegbarkeit von pharmazeutischen wirkstoffen mit peptidbindungen
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4131562A1 (de) 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
AU699192B2 (en) * 1993-08-13 1998-11-26 Bayer Corporation Hydrolyzed gelatin as a flavor enhancer in a chewable tablet
AU7655194A (en) * 1993-09-09 1995-03-27 Schering Aktiengesellschaft Active principles and gas containing microparticles
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
ES2078190B1 (es) * 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275796A1 (de) * 1986-12-31 1988-07-27 Centre National De La Recherche Scientifique Herstellungsverfahren für kolloid-disperse Systeme aus einer Substanz in Form von Nanopartikeln
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO1995005164A1 (en) * 1993-08-12 1995-02-23 Kirsten Westesen Particles with modified physicochemical properties, their preparation and uses
WO1998014174A1 (en) * 1996-10-01 1998-04-09 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
WO2000033820A2 (de) 2000-06-15
DE19856432A1 (de) 2000-06-15
US7687071B1 (en) 2010-03-30
JP2002531492A (ja) 2002-09-24
CN100346775C (zh) 2007-11-07
CN1334724A (zh) 2002-02-06
CA2353809A1 (en) 2000-06-15
EP1137404A2 (de) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2000033820A3 (de) Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen
PL327767A1 (en) Drugs containing known auxiliary substances and an active substance
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
HK1039054A1 (en) Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug.
CA2199249A1 (en) Laminated tablet with pointed core
EP0667148A4 (de) Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt.
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
DE68913461D1 (de) Wässrige Verteilung, Verbundpulver und Organosol vom Fluorid enthaltenden Polymerisat.
AU4359096A (en) An inhalation device, a method of dispersing a pharmaceutically active substance and a method of administering a dose of pharmaceutically active substance
AU2300699A (en) Amidino derivatives and drugs containing the same as the active ingredient
CA2298659A1 (en) Fast-acting analgesic
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
EP0392426A3 (de) Emulgatorfreie Hand- und Körperlotion
AU1265097A (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
HK1032010A1 (en) Medicament formulation with a controlled release of an active agent.
EP0960885A4 (de) Depsipeptide und medikamente, welche dieselben als aktive ingredienzien enthalten
AU1671799A (en) Medicament preparation in the form of a tablet or pellet for acid-labile active substances
AU8784398A (en) Encapsulation of living tissue cells in a microsphere
EP1044681A3 (de) Carbamazepinformulierung mit verzögerter Freigabe
EP0725092A3 (de) Redispergierbare, pulverförmige Kern-Mantel-Polymere, deren Herstellung und Verwendung
AU6100194A (en) Active drug delivery device, electrode, and method for making same
EP1210942A3 (de) Micropartikel
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
NZ228233A (en) Controlled release system comprising an active substance and a weighting agent together in a biodegradable matrix, and preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99816078.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999963399

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 586313

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2353809

Country of ref document: CA

Ref document number: 2353809

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999963399

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09857480

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: 1999963399

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999963399

Country of ref document: EP